Mitochondria require all translational components, including aminoacyl-tRNA synthetases (aaRSs), to complete organelle protein synthesis. Some aaRS mutations cause mitochondrial disorders, including human mitochondrial threonyl-tRNA synthetase (hmtThrRS) (encoded by TARS2), the P282L mutation of which causes mitochondrial encephalomyopathies. However, its catalytic and structural consequences remain unclear. Herein, we cloned TARS2 and purified the wild-type and P282L mutant hmtThrRS. hmtThrRS misactivates non-cognate Ser and uses post-transfer editing to clear erroneously synthesized products. In vitro and in vivo analyses revealed that the mutation induces a decrease in Thr activation, aminoacylation, and proof-reading activities and a change in the protein structure and/or stability, which might cause reduced catalytic efficiency. We also identified a splicing variant of TARS2 mRNA lacking exons 8 and 9, the protein product of which is targeted into mitochondria. In HEK293T cells, the variant does not dimerize and cannot complement the ThrRS knock-out strain in yeast, suggesting that the truncated protein is inactive and might have a non-canonical function, as observed for other aaRS fragments. The present study describes the aminoacylation and editing properties of hmtThrRS, clarifies the molecular consequences of the P282L mutation, and shows that the yeast ThrRS-deletion model is suitable to test pathology-associated point mutations or alternative splicing variants of mammalian aaRS mRNAs.

This process starts with amino acid activation by condensation with ATP to form the aminoacyl adenylate aa-AMP and pyrophosphate. The activated amino acid then reacts with the 3’-end of the cognate tRNA to yield the aminoacyl-tRNA (aa-tRNA), which is transferred by EF-Tu to the protein biosynthesis machinery as a building block. Highly accurate protein synthesis is indispensable for cell growth. To maintain fidelity during protein synthesis, aaRS needs to select the correct amino acid and tRNA substrates from a large number of structurally similar molecules in the cells. The specificity of aaRS is greatly challenged by the presence of the 20 amino acids in which the physicochemical properties are sometimes very similar and by non-proteogenous amino acids and diverse metabolites produced by cell metabolism. aaRSs that do not show an overall selectivity above 1 in 3000 are predicted to require proofreading (editing) activity to maintain sufficient accuracy during aa-tRNA synthesis (3). In fact, editing activity has evolved in half of the currently identified aaRS to remove aberrantly produced aa-AMP (pretransfer editing) and/or aa-tRNA (post-transfer editing) (4). tRNA mischarging may be toxic and deleterious for cells. Even a slight decrease in aminoacylation accuracy could cause an intracellular accumulation of misfolded proteins and up-regulation of cytoplasmic protein chaperones in neurons, leading to severe mammalian neurodegeneration (5). Mistranslation arising from disruption of translational fidelity also has profound consequences in Escherichia coli (6, 7) and mammalian cells (8).

Mitochondria play a key role in cell growth, such as the regulation of nitrogen metabolism and programmed cell death (9). In addition, they provide most of the cellular energy by oxidative phosphorylation (OXPHOS) and act as cellular power plants. In particular, mitochondria possess their own genome. Human mitochondrial DNA (mtDNA) is a small circular molecule of 16,569 bp. It encodes 13 polypeptides that are essential subunits of respiratory complexes, 22 tRNA, and two rRNA (10, 11). Except for two tRNALeu or tRNASer iso-acceptors, the other amino acids have only one corresponding tRNA (such as one mitochondrial tRNAThr(UGC)) for protein synthesis. MtDNA undergoes mutations at a higher rate than nuclear genomes because of the presence of reactive oxygen species, its freedom from histones, and lack of repair mechanisms (12, 13). Over the last decade, more than 200 point mutations and rear-
A Point Mutation in hmtThrRS Induces Functional Defects

rangements associated with a large number of a wide spectrum of clinical abnormalities have been reported (14). However, over half of these mutations occurred in tRNA genes (15). In addition, mitochondrial aaRSs encoded by the nuclear genome are key components of the mitochondrial protein synthesis system. They are synthesized in the cytoplasm, imported into and function in the mitochondria (16).

ThrRSs are present in all three domains of life and usually contain an N-terminal N1 domain, an N2 domain (for editing), an aminoacylation domain (for amino acid activation and tRNA charging), and an anticodon binding domain (for tRNA binding) (17). Based on an alignment of primary sequences, bacterial ThrRSs display an obvious difference to eukaryotic ThrRSs in the N-terminal N1 and N2 (editing) domains. Interestingly, despite the bacterial origin of mitochondria, human mitochondrial ThrRS (hmtThrRS) is more similar to eukaryotic cytoplasmic ThrRS. hmtThrRS is encoded by the TARS2 gene. Bacterial and eukaryotic cytoplasmic ThrRS, shown to misactivate non-cognate Ser, mainly use an efficient post-transfer editing activity to clear mischarged Ser-tRNA^Thr^ in addition to tRNA-dependent pretransfer editing (18–20). In contrast, Saccharomyces cerevisiae mitochondrial ThrRS (ScmtThrRS) naturally lacks an editing domain and only harbors tRNA-independent and tRNA isoacceptor-specific pretransfer editing (21, 22). As a result, ScmtThrRS lacks post-transfer editing and is an error-prone synthetase, forming Ser-tRNA^Thr_, at least in vitro (22). Several bacterial or cytoplasmic aaRSs are critically dependent upon their editing activity to achieve accurate aminoacylation. However, in several cases, the corresponding human mitochondrial enzymes carry non-functional editing sites or lack editing domains, raising the question of their aminoacylation fidelity. In fact, these enzymes achieve fidelity using a more specific amino acid binding pocket, reducing the need of editing activity. This enhanced specificity compensating for the presence of a defunct editing site has been identified in human mitochondrial LeuRS (23) and S. cerevisiae mitochondrial PheRS (24, 25).

Concerning hmtThrRS encoded by TARS2, no information is available on its aminoacylation editing activities. According to the increasing number of mutations in aaRS genes causing mitochondrial dysfunctions, including hmtThrRS (26), there is an interest in analyzing the functional properties of these molecules and developing new tools to examine their in vivo properties. Recently, two mutations (c.845C>T, encoding hmtThrRS-P282L and a nucleotide change in position +3 of intron 6 (g.4255A>G; c.695 + 3A>G)) were identified in TARS2 in two siblings presenting axial hypotonia and severe psychomotor delay associated with multiple mitochondrial respiratory chain defects (26). Both hmtThrRS protein and aminoacylated tRNA^Thr^ levels are decreased in the patients’ cells. The g.4255A>G mutation has no influence in mRNA splicing (26); therefore, it was proposed that the c.845C>T mutation is responsible for patient phenotypes. However, how the mutation affects protein structure, stability, and catalytic activities remains largely unknown.

In this study, we cloned TARS2, encoding the hmtThrRS precursor, and purified soluble hmtThrRS. In yeast, we found that the only S. cerevisiae tRNA^Thr^ is not an efficient substrate for hmtThrRS. To be used as an in vivo functional assay in yeast, we found that an extra human tRNA had to be added. We also showed that hmtThrRS misactivates non-cognate Ser, and a robust pretransfer editing, in addition to post-transfer editing, prevents the formation of mischarged tRNA. In addition, we explored the effect of mutation of Pro^282_ in detail and found that the mutant hmtThrRS-P282L causes an obvious decrease in amino acid activation, tRNA^Thr^ aminoacylation, and editing. Furthermore, we revealed that the mutation alters the structure and/or stability of the protein. Finally, in several cell lines, we identified a splicing variant of TARS2 encoding a truncated, catalytically inactive hmtThrRS. The variant is readily translated and imported into mitochondria, suggesting a noncanonical mitochondrial function. This phenomenon is reminiscent of other examples of synthetase fragments and supports the hypothesis that alternative splicing of mRNA transcripts of aaRS is a way to enlarge aaRS additional functions in higher eukaryotes (27, 28). Altogether, our results significantly improve our understanding of hmtThrRS and provide a basis for further investigations of TARS2-related human diseases.

Experimental Procedures

Materials—L-Thr, L-Ser, dithiothreitol, NTP, GMP, tetrasodium pyrophosphate, inorganic pyrophosphate, Tris-base, MgCl2, NaCl, and activated charcoal were purchased from Sigma. [14C]Thr was obtained from Biotrend Chemicals (Destin, FL), and [14C]Ser and [α-32P]ATP were obtained from PerkinElmer Life Sciences. The DNA fragment rapid purification kits and plasmid extraction kits were purchased from Yuanyinghao Biotech. KOD-plus mutagenesis kits were obtained from Toyobo. T4 DNA ligase and restriction endonucleases were obtained from Thermo Fisher Scientific. Phusion high-fidelity DNA polymerase was purchased from New England Biolabs. Ni2^+^-NTA Superflow was purchased from Qiagen Inc. Polyethyleneimine cellulose plates were purchased from Merck. Pyrophosphatase (PPIase) was obtained from Roche Applied Science. The dNTP mixture was obtained from Takara. Oligonucleotide primers were synthesized by Invitrogen. E. coli BL21(DE3) cells were purchased from Stratagene. The yeast transformation kit was purchased from Clontech. Mouse anti-FLAG (M20008, anti-His6 tag (M20001), anti-GAPDH (M20028), and anti-c-Myc (M20002) antibodies were purchased from Abmart.

Gene Cloning, Mutagenesis, Expression, and Protein Purification—The TARS2 coding sequence was amplified from cDNA obtained by RT-PCR from total RNA obtained from HEK293T cells and cloned into pET28a(+) with an N-terminal His6 tag and named pET28a(+)-TARS2. pET28a(+)-TARS2 was used as the template to construct N-terminal truncation mutants. Gene mutagenesis was performed according to the protocol provided with the KOD-plus mutagenesis kit. E. coli BL21(DE3) was transformed with various constructs. Protein purification was performed according to a previously described method (29).

tRNA Gene Cloning and Transcription—The DNA sequences of the T7 promoter and the hmttRNA^Thr^ (UGU) gene were obtained by ligating two chemically synthesized DNA fragments for each strand, which were then ligated into the.
pTrc99b plasmid (precleaved with EcoRI/PstI) to construct pTrc99b-T7-hmttRNA<sup>Thr</sup>(UGU). Then, the template was amplified for transcription in vitro using Phusion polymerase and the forward primer (5’-CACAGGAAACAGACATGGG-AATTCC 3’) and reverse primer (5’-TGGTGTCCTGGAA-AAAGTGTTCATCCTC 3’). hmttRNA<sup>Thr</sup> transcripts were obtained using the T7 RNA polymerase run-off procedure as described previously (7).

**Yeast Complementation Assay, Preparation of Yeast Cell Lysates, and Western Blotting**—For complementation assays, all genes of interest were cloned into the yeast expression vector, p425TEF and fused with a DNA fragment encoding a C-terminal His<sub>6</sub> tag to facilitate protein level determination using an anti-His<sub>6</sub> antibody. The hmtThrRS construct or the hmtThrRS plus hcttRNA<sup>Thr</sup>(AGU) constructs were transformed separately into the ScΔthrS strain (BY4743, thrS<sup>r</sup>), pRS426-ScThrRS. Transformants were selected on SD/Ura<sup>r</sup>/Leu<sup>r</sup> plates or SD/Ura<sup>r</sup>/Leu<sup>r</sup>/His<sup>r</sup> plates (for co-expression of hcttRNA<sup>Thr</sup>(AGU)), and a single clone was cultured in liquid SD/Leu<sup>r</sup> or SD/Leu<sup>r</sup>/His<sup>r</sup> medium. The culture was then diluted to a concentration of 1 OD<sub>600</sub> (5 × 10<sup>8</sup> cells/ml); a 10-fold dilution series of the yeast cells was plated onto the SD/Leu<sup>r</sup>/5-FOA or SD/Leu<sup>r</sup>/His<sup>r</sup>/5-FOA medium to induce the loss of the rescuing plasmid (pRS425-ScthrS) and was grown for 3 days on 30 °C. The same procedure was used to check whether hmtThrRS variants could support the growth of the ScΔthrS strain.

Yeast transformants were grown in liquid SD/Leu<sup>r</sup>/Ura<sup>r</sup> or SD/Leu<sup>r</sup>/Ura<sup>r</sup>/His<sup>r</sup>. Yeast cells were lysed following a previously described method (30). Recombinant proteins in the cell lysates were detected by Western blotting with anti-His<sub>6</sub> antibodies.

**ATP-PP<sub>e</sub>, Exchange Assay**—The ATP-PP<sub>e</sub>, exchange measurement was carried out at 37 °C in a reaction mixture containing 60 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 5 mM DTT, 0.1 mg/ml BSA, 2.5 mM ATP, 2 mM tetrasodium [<sup>32</sup>P]pyrophosphate, 0.5–20 mM Thr or 50–800 mM non-cognate Ser, and 200 nM hmtThrRS or its variants. Samples of the reaction mixture were removed at specific time points and added into 200 μl of quenching solution containing 2% activated charcoal, 3.5% HClO<sub>4</sub>, and 50 mM tetrasodium pyrophosphate. The solution was filtered through a Whatman GF/C filter followed by washing with 50 ml of 200 mM NaAc (pH 5.2), dried at room temperature for 30 min, and dissolved in 5 mM MgCl<sub>2</sub>, 2 mM DTT, 4 mM ATP, 50 mM unlabeled hmttRNA<sup>Thr</sup>, 5 μM [<sup>32</sup>P]hmttRNA<sup>Thr</sup>, 500 mM Ser, and 10 μM hmtThrRS-H133A/H137A for 1 h. The solution was then extracted twice using phenol/chloroform and precipitated in 3 volumes of ethanol.

[<sup>32</sup>P]hmttRNA<sup>Thr</sup> was incubated with Ser at 37 °C in a reaction mixture containing 60 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 2 mM DTT, 4 mM ATP, 5 μM unlabeled hmttRNA<sup>Thr</sup>, 1.5 μM [<sup>32</sup>P]hmttRNA<sup>Thr</sup>, 500 mM Ser, and 10 μM hmtThrRS-H133A/H137A for 1 h. The solution was then extracted twice using acid phenol (pH4.5)/chloroform and precipitated in 3 volumes of 100% ethanol at −20 °C overnight. The precipitated sample was centrifuged (12,000 × g) at 4 °C for 30 min, dried at room temperature for 30 min, and dissolved in 5 mM MgCl<sub>2</sub>. The ratio of Ser-[<sup>32</sup>P]hmttRNA<sup>Thr</sup> was determined by liquid scintillation counting of the sample washed with and without 5% trichloroacetic acid.

**Post-transfer Editing**—Post-transfer editing of preformed Ser-[<sup>32</sup>P]hmttRNA<sup>Thr</sup> was performed in a reaction mixture containing 60 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 μM Ser-[<sup>32</sup>P]hmttRNA<sup>Thr</sup>, and 200 nM hmtThrRS or its variants at 37 °C. Samples at specific time points were taken for ethanol precipitation with NaAc (pH 5.2) at −20 °C overnight. The precipitated samples were centrifuged (12,000 × g) at 4 °C for 30 min, dried at room temperature for 30 min, and digested with 6 μl of nuclease S1 (25 units) for 2 h at 37 °C. After nuclear S1 digestion, samples (2 μl) of the digestion mixture were loaded and separated by TLC in 0.1 M NH<sub>4</sub>Ac and 5% acetic acid. The plates were visualized by phosphorimaging, and the data were analyzed using MultiGauge version 3.0 software (Fujifilm).

**AMP Formation Assay**—The AMP formation assay (using TLC) was carried out at 37 °C in a reaction mixture containing 60 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 5 mM DTT, 0.1 mg/ml BSA, 10 units/ml PPiase, 40 mM Ser (or 4 mM Thr), 3 mM [<sup>32</sup>P]ATP, and 2 μM hmtThrRS or its variants. AMP-<sup>32</sup>P was detected in the presence and absence of hmttRNA<sup>Thr</sup>. Samples (1.5 μl) at specific time points were quenched in 6 μl of 200 mM NaAc (pH 5.2). The quenched aliquots (1.5 μl of each sample) were spotted on polyethyleneimine cellulose plates prewashed with water. The separation of Ser-[<sup>32</sup>P]AMP, [<sup>32</sup>P]AMP, and [<sup>32</sup>P]ATP was performed in 0.1 M NH<sub>4</sub>Ac and 5% acetic acid. The plates were visualized by phosphorimaging, and the data were analyzed using MultiGauge version 3.0 software (Fujifilm). Quantification of [<sup>32</sup>P]AMP was achieved by densitometry in comparison with [<sup>32</sup>P]ATP samples of known concentrations.

**Quantitative Real-time PCR (qPCR) of hmtThrRS-SV from cDNA Libraries of Different Cell Lines**—hmtThrRS-SV was identified as a novel splicing variant of FARS2 (see “Results”). Human total RNA from five cell lines was extracted using a TRIzol Plus RNA purification kit (Life Technologies) and then used to synthesize cDNA libraries using the SuperScript III First Strand synthesis kit (Life Technologies). Primer pair 1, targeting exons 8 and 9, was used to detect the native transcripts; primer 1-F, CACACACAGAATTGCTGGAGG; primer 1-R, AGGGCTCAGTCTGAGAGA; primer 2-R, CATACTAGCGATACAGC.

**A Point Mutation in hmtThrRS Induces Functional Defects**

Aminoacylation—Aminoacylation kinetics were performed at 37 °C in a reaction mixture containing 60 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 5 mM DTT, 0.1 mg/ml BSA, 2.5 mM ATP, 2 mM tetrasodium [<sup>32</sup>P]pyrophosphate, 0.5–20 mM Thr or 50–800 mM non-cognate Ser, and 200 nM hmtThrRS or its variants. Samples of the reaction mixture were removed at specific time points and added into 200 μl of quenching solution containing 2% activated charcoal, 3.5% HClO<sub>4</sub>, and 50 mM tetrasodium pyrophosphate. The solution was filtered through a Whatman GF/C filter followed by washing with 20 ml of Milli-Q water and 10 ml of 100% ethanol. The filters were dried, and [<sup>32</sup>P]ATP was counted in a scintillation counter (Beckman Coulter).

**Aminoacylation and Misaminoacylation**—In vitro aminoacylation and misaminoacylation of hmttRNA<sup>Thr</sup> at 37 °C in a mixture containing 60 mM Tris-HCl (pH 8.0), 10 mM MgCl<sub>2</sub>, 10 μM hmttRNA<sup>Thr</sup>, 0.5 mM DTT, 5 μM ATP, 50 μM tetrasodium pyrophosphate, 0.66 μM [α<sup>32</sup>P]ATP, and 10 μM CCA-adding enzyme (CCase) for 5 min. Then, 0.1 unit of PPiase was added to the mixture for 5 min. The solution was then extracted twice using phenol/chloroform and precipitated in 3 volumes of ethanol.

[<sup>32</sup>P]hmttRNA<sup>Thr</sup> was incubated with Ser at 37 °C in a reaction mixture containing 60 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 2 mM DTT, 4 mM ATP, 5 μM unlabeled hmttRNA<sup>Thr</sup>, 1.5 μM [<sup>32</sup>P]hmttRNA<sup>Thr</sup>, 500 mM Ser, and 10 μM hmtThrRS-H133A/H137A for 1 h. The solution was then extracted twice using acid phenol (pH4.5)/chloroform and precipitated in 3 volumes of 100% ethanol at −20 °C overnight. The precipitated sample was centrifuged (12,000 × g) at 4 °C for 30 min, dried at room temperature for 30 min, and dissolved in 5 mM MgCl<sub>2</sub>. The ratio of Ser-[<sup>32</sup>P]hmttRNA<sup>Thr</sup> was determined by liquid scintillation counting of the sample washed with and without 5% trichloroacetic acid.
A Point Mutation in hmtThrRS Induces Functional Defects

qPCR was carried out using SYBR GreenER qPCR SuperMix kits (Life Technology) on an ABI 7500 instrument, set as follows: 1 min at 95 °C followed by 40 cycles of 95 °C for 15 s, 60 °C for 30 s, and then 72 °C for 45 s. A default melt curve program was run at the end of the qPCR cycles to verify the specificity of the PCR reaction. A single amplicon of the correct size of target DNA fragment was detected by agarose gel electrophoresis. The amplification efficiency was nearly 95%, which was determined from a calibration curve based on the Ct values and different concentrations of cDNA template. qPCR values obtained for each cell line were normalized to GAPDH mRNA levels. The relative amount of hmtThrRS-SV was calculated using the ∆∆Ct method from the qPCR values of hmtThrRS and hmtThrRS-SV (31).

Cell Transfection and Fluorescence Microscopy—HEK293T cells were transfected with the FLAG-tagged constructs of pCMV-3Tag-3A-TARS2 or pCMV-3Tag-3A-hmtThrRS-SV precursor according to a previously described method (32). After transfection for 24 h, cells were stained with 100 nm MitoTracker (Life Technologies, M-7512) for 20 min and then fixed in PBS containing 4% paraformaldehyde for 30 min. Fixed cells were blocked in PBS plus 0.1% Triton X-100 buffer containing 5% BSA and incubated with mouse anti-FLAG antibodies overnight at 4 °C. The cells were then immunostained with Alexa Fluor 647-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch, 715-605–150) and the nuclear counterstain DAPI. Fluorescent images were taken and analyzed using an FV1000 confocal microscope (Olympus).

Co-immunoprecipitation and Western Blotting Assay—The coding sequences of TARS2 and hmtThrRS-SV precursor were cloned into eukaryotic expression vectors pCMV-3Tag-3A (with a C-terminal 3 × FLAG tag) and pCMV-3Tag-4A (with a C-terminal 3 × c-Myc tag). Plasmid pCMV-3Tag-4A-hmtThrRS precursor, together with either pCMV-3Tag-3A-hmtThrRS precursor or pCMV-3Tag-3A, was co-transfected into HEK293T cells using Lipofectamine 2000 to express the genes of FLAG- or c-Myc-hmtThrRS as described previously (32). The same method was used to express the hmtThrRS-SV precursor coding sequence. After transfection for 36 h, cells were lysed and incubated with anti-FLAG antibodies to immunoprecipitate hmtThrRS, as described previously (32). Cell lysates and immune complexes were separated and immunoblotted with either anti-FLAG or anti-c-Myc antibody.

Filter Binding Assays—The complex formation of hmtThrRS and [32P]hmttRNAThr or hmtThrRS-P282L and [32P]hmttRNAThr was monitored using the classical filter binding method reported by Berg and co-workers (33, 34). A Millipore nitrocellulose membrane (0.22 μm) was equilibrated in washing buffer (50 mM potassium phosphate (pH 5.5), 50 mM MgCl₂) for at least 10 min before use. Radiolabeled [32P]hmttRNAThr (20 nm, 25,000 cpm) was incubated in 50 μl of binding buffer (50 mM HEPES-KOH (pH 6.8), 30 mM KCl, 12 mM MgCl₂) in the presence of various concentrations of hmtThrRS or hmtThrRS-P282L for 30 min at 4 °C. Upon RNA-protein association, samples were filtered through the pre-equilibrated nitrocellulose membranes. The filters were then washed twice with 0.3 ml of the washing buffer and air-dried before radioactive quantification. All of the data were analyzed using GraphPad Prism software.

Circular Dichroism (CD) Analysis of hmtThrRS and hmtThrRS-P282L—CD spectroscopy experiments were performed on a Jasco J-715 spectropolarimeter between wavelengths 190 and 250 nm at room temperature. Samples (0.2 mg/ml) were diluted and incubated in the assay buffer (5 mM Tris-HCl (pH 8.0), 5 mM NaCl). A 0.1-cm path length was used, and spectra were accumulated over five scans. Background signals from the cuvette and the buffer were subtracted from each spectrum. The data were analyzed using OriginLab software.

Measurement of the Thermal Stability of hmtThrRS and hmtThrRS-P282L—hmtThrRS and hmtThrRS-P282L were heated at 50 °C for increasing incubation times (1, 2, 3, 4, 5, and 10 min) and kept on ice. The aminocytation activity of the two proteins was then measured at 37 °C in a reaction mixture containing 60 mM Tris-HCl (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.1 mg/ml BSA, 2.5 mM ATP, 100 μM [14C]Thr, 5 μM hmttRNAThr, and 200 μM enzyme. The activity of the enzymes before heating was designated as 100%. All experiments were independently repeated three times.

Results

Cloning and Expression of TARS2—The hmtThrRS precursor, comprising 718 amino acid residues, is encoded by the nuclear gene TARS2, which is located at chromosome 1q21.3. TARS2 is transcribed in the nucleus and translated in the cytoplasm, and then the hmtThrRS precursor is transported into mitochondria via its mitochondrial targeting sequence (MTS). As revealed by primary sequence alignment, the hmtThrRS precursor resembles eukaryotic ThrRS more than its bacterial counterparts, illustrated by the conservation of the N-terminal extension and N1 and N2 editing domains. Aminoacylation and the anticodon binding domains are conserved among eukaryotic and bacterial ThrRSs.

Despite its being identified almost 10 years ago (35), no study has reported the cloning and expression of TARS2. To predict the N-terminal sequence of the mature protein, we used the algorithm MITOPROT (47), which calculates the N-terminal protein region that supports an MTS and the cleavage site. MitoProt predicted an MTS from Met1 to Leu38. Therefore, we cloned the DNA sequence encoding Phe39–Phe718 into pET28a (+). However, hmtThrRS∆Δ38 exclusively formed inclusion bodies under various expression conditions, and changes in the expression vectors or strains did not improve the solubility of the protein. Assuming that the mature form of hmtThrRS might not start as predicted at residue 39, we constructed three sequential deletions targeting the N terminus to obtain hmtThrRS∆N19, hmtThrRS∆N25, and hmtThrRS∆N58. The results showed that only hmtThrRS∆N19 was successfully expressed in a soluble form and at a significant level. After purification, hmtThrRS∆N19 reached over 95% purity (Fig. 1A) and displayed obvious activity in catalyzing ThrRNAThr formation (Fig. 1B) (aminocytation kinetics are presented in subsequent sections below). Its charging activity indicated that hmtThrRS∆N19 should be a homodimer, like other ThrRS (36). This result suggested that the cleavage of the MTS from the hmtThrRS precursor takes place at or near this posi-
whether the newly identified deletion TARS2-Δ38 was able to rescue the strain Sc\textit{ΔthrS}. However, under the same conditions, TARS2-Δ38 also failed to rescue the knock-out strain (Fig. 2E). Considering the inability of hmtThrRS to aminoacylate SctRNA\textsuperscript{Thr} (AGU) \textit{in vitro} (see above), we hypothesized that ACU codons cannot be properly decoded \textit{in vivo}, leading to the lethality of strain Sc\textit{ΔthrS}. Indeed, \textit{S. cerevisiae} harbors 17 genes for tRNA\textsuperscript{Thr} among which 11 are for tRNA\textsuperscript{Thr} (AGU), demonstrating its abundance and crucial importance for protein translation in yeast. To this end, we simultaneously expressed TARS2-Δ38 or TARS2-Δ38 and the human hctRNA\textsuperscript{Thr} (AGU) gene in Sc\textit{ΔthrS} to assess the ability of the human synthetase and tRNA to restore the growth phenotype. Under selective conditions, the combination of TARS2-Δ38 and hctRNA\textsuperscript{Thr} (AGU) rescued the growth of Sc\textit{ΔthrS} (Fig. 2E), suggesting that hctRNA\textsuperscript{Thr} (AGU) was aminoacylated by hmtThrRS in yeast and could decode the corresponding codons \textit{in vivo}. Under the same conditions, TARS2-Δ38 failed to support growth, despite the presence of overexpressed hctRNA\textsuperscript{Thr} (AGU) (Fig. 2E). Collectively, these data confirmed that the inability of hmtThrRS to replace Sc\textit{ThrS} in \textit{in vivo} is likely caused by its inability to charge SctRNA\textsuperscript{Thr} (AGU).

\textbf{Amino Acid Activation Activity of hmtThrRS—} Amino acid activation is the first step of tRNA aminoacylation, and the accurate selection of cognate amino acid activation by aaRS is indispensable for accurate protein synthesis. To date, various ThrRSs, including \textit{E. coli} ThrRS (EcThrRS), \textit{S. cerevisiae} ThrRS (ScThrRS), and \textit{S. cerevisiae} mitochondrial ThrRS (Smmt-ThrRS), have been reported to misactivate non-cognate Ser (19, 20, 22). On the other hand, several mitochondrial tRNA synthetases (such as LeuRS or PheRS) exhibit a stricter amino acid selection ability (23–25). To reveal the amino acid activation activity of hmtThrRS, we measured the activation kinetics of hmtThrRS for cognate Thr and non-cognate Ser and found that hmtThrRS has a much higher \(k_{\text{cat}} \) value for Ser (180 ± 14 mm) compared with Thr (2.5 ± 0.1 mm) and that the \(k_{\text{cat}} \) value for Thr is 5-fold greater than that for Ser ((5.8 ± 0.2 s\(^{-1}\)) and (1.1 ± 0.02 s\(^{-1}\)), respectively) (Table 1). These data correspond to a discrimination factor of 383 in favor of Thr (Table 1); this is relatively low and not consistent with the overall \textit{in vivo} rate of misincorporation during protein synthesis, which has been estimated to be in the range of 6 × 10\(^{-4}\) to 5 × 10\(^{-3}\)/amino acid incorporated (38, 39). In addition, the free Ser concentration slightly exceeds that of free Thr in mammalian mitochondria (1.81 and 1.33 nmol/mg of protein, respectively) (40), indicating that misactivation should be even higher \textit{in vivo}. Altogether, these data showed that Ser might be misactivated by hmtThrRS \textit{in vivo}, over the threat alert level for accurate decoding of Thr codons in human mitochondria. Low fidelity protein synthesis usually leads to increased amounts of unfolded proteins in the cells (6); therefore, it is likely that proofreading of the misactivated Ser would occur before and/or after its transfer onto tRNA\textsuperscript{Thr}.

\textbf{Editing Properties of hmtThrRS—} Usually one AMP molecule is formed per aminoacyl-tRNA produced during the aminoacylation reaction. In the presence of a non-cognate amino acid and a proofreading activity, the non-cognate adenylate or mischarged tRNA is hydrolyzed, releasing one AMP molecule per

\textbf{FIGURE 1. Purification of an active hmtThrRS.} A, SDS-PAGE analysis of purified hmtThrRS. B, time course curve of aminoacylation of hmttRNA\textsuperscript{Thr} by hmtThrRS. The control was performed without enzyme addition. Error bars, S.D.
non-cognate amino acid activated or charged. The repetitive cycles of synthesis-hydrolysis of the non-cognate products consume more ATP and release proportional amounts of AMP, the quantification of which by TLC allows monitoring of the proof-reading/editing activities. When performed in the presence of tRNA, the TLC assay measures all of the editing activities combined, including tRNA-independent and -dependent pretransfer editing, in addition to the post-transfer editing. In the absence of tRNA, the assay measures the AMP produced from the sole tRNA-independent pretransfer editing activity. With hmtThrRS and Ser as the non-cognate amino acid, in the absence or presence of hmttRNAThr, the observed rate value ($k_{\text{obs}}$) of AMP formation was $(3.5 \pm 0.04) \times 10^{-3}$ s$^{-1}$ and $(18.9 \pm 0.2) \times 10^{-3}$ s$^{-1}$, respectively (Table 2 and Fig. 3A).

Therefore, the AMP formation of hmtThrRS derives mainly from tRNA-dependent editing, which includes tRNA-dependent pretransfer and/or post-transfer editing. To identify the origin of the AMP formation, we inactivated the two critical His residues of the editing domain of ThrRS that are directly involved in post-transfer editing (20, 41). Based on sequence alignments, we constructed a double mutant targeting His133 and His137 of hmtThrRS (equivalents of His73 and His77 in EcThrRS) to obtain the double mutant hmtThrRS-H133A/H137A. In the TLC assay, it catalyzed AMP formation with $k_{\text{obs}}$ values of $(3.0 \pm 0.3) \times 10^{-3}$ s$^{-1}$ and $(17.0 \pm 0.2) \times 10^{-3}$ s$^{-1}$ in

---

**TABLE 1**

Kinetic parameters of hmtThrRS for threonine and serine in the activation reaction as measured by an ATP-PPi exchange reaction

| Amino acid | $k_{\text{cat}}$ | $K_m$ | $k_{\text{cat}}/K_m$ | Discrimination factor |
|------------|-----------------|-------|---------------------|----------------------|
| Thr        | 5.8 ± 0.2       | 2.5 ± 0.1 | 2.3 | 1 |
| Ser        | 1.1 ± 0.02      | 180 ± 14 | 0.006 | 383 |

**TABLE 2**

$k_{\text{obs}}$ of AMP formation of hmtThrRS and its variants in the presence of Ser

| Enzyme       | tRNA                        | $k_{\text{obs}}$ ($\times 10^{-3}$) | Relative $k_{\text{obs}}$ % |
|--------------|-----------------------------|-----------------------------------|-----------------------------|
| hmtThrRS     | +                           | 18.9 ± 0.2                        | 100 |
| H133A/H137A  | +                           | 3.5 ± 0.04                        | 100 |
| P282L        | +                           | 2.8 ± 0.2                         | 15 |

---

**FIGURE 2.** hmttRNAThr determinants for aminoacylation and cross-species recognition of tRNA Thr by hmtThrRS. A, cloverleaf structure of hmttRNAThr(UGU) with mutations indicated. B, aminoacylation of hmttRNAThr(UGU) and its mutants, including G35C, U36C, and A73C, by hmtThrRS. The control curve was obtained without tRNA addition. C, aminoacylation of hmttRNAThr(UGU), hctRNAThr(AGU), Sc tRNAThr(AGU), Sc tRNAThr(CGU), and Sc tRNAThr(UGU), and control (without adding tRNA) by hmtThrRS. D, cloverleaf structures of Sc tRNAThr(AGU) and hctRNAThr(AGU). E, complementation phenotypes of hmtThrRS mutations with hctRNAThr(AGU). Drop test of Sc thrS strain expressing hmtThrRS-D19 and hmtThrRS-D38 with hctRNAThr(AGU). Strains harboring empty p425TEF or empty p413GPD were used as negative controls. Error bars, S.D.
A Point Mutation in hmtThrRS Induces Functional Defects

FIGURE 3. Editing and mischarging properties of hmtThrRS and the mutated derivative hmtThrRS-H133A/H137A. A, AMP formation by hmtThrRS and the double mutant in the presence of non-cognate Ser and in the presence or absence of tRNA. [32P]AMP was quantified after TLC separation on PEI plates. B, deacylation of Ser-[32P]hmttRNA*Thr by hmtThrRS and the double mutant hmtThrRS-H133A/H137A. The control without enzyme represents the spontaneous hydrolysis of mischarged tRNA. After incubation with ThrRS, the samples were treated by nuclease S1, and Ser-[32P]AMP was quantified after TLC separation. C, mischarging of hmttRNAThr by [14C]Ser catalyzed by hmtThrRS and the double mutant. The control curve was obtained without enzyme addition. Error bars, S.D.

the absence or presence of hmttRNA*Thr, respectively (Table 2 and Fig. 3A). Because the double mutant was supposed to be deprived of post-transfer activity, these nearly unchanged values suggested that the post-transfer editing only moderately contributes to total editing, whereas the majority of the AMP formed is derived from tRNA-dependent pretransfer editing.

To confirm this deduction, we measured the deacylation activity of a preformed Ser-[32P]tRNA*Thr. After nuclease S1 treatment, Ser-[32P]AMP was separated from [32P]AMP by TLC, and the deacylation activity was calculated. The assay showed that hmtThrRS has the capability to deacylate the mischarged tRNA, as expected from the post-transfer editing activity (Fig. 3B). However, deacylation of preformed Ser-tRNA*Thr showed that post-transfer editing of hmtThrRS-H133A/H137A is absent (Fig. 3B). Indeed, the mutant hmtThrRS-H133A/H137A formed much more Ser-tRNA*Thr than the wild-type hmtThrRS enzyme (Fig. 3C).

Thus, tRNA-independent pretransfer editing and post-transfer editing contribute little to the total editing, whereas majority of formed AMP is derived from tRNA-dependent pretransfer editing. However, post-transfer editing is the most efficient and critical safeguard to prevent Ser-tRNA*Thr synthesis, as demonstrated by its accumulation by hmtThrRS-H133A/H137A.

Analysis of Mitochondrial Disease-causing Pro to Leu Mutation at Position 282—Recently, a novel site mutant, P282L, in hmtThrRS was identified that potentially causes mitochondrial disease. Pro282 of the hmtThrRS precursor is absolutely conserved among eukaryotic ThrRS (Fig. 4A). In the bacterial EcThrRS structure (Protein Data Bank code 1QF6), the corresponding residue is located in a turn between the N2 editing domain and the peptide connecting the aminoaacylation domain (Fig. 4B). Since Pro282 is located in such a crucial turn linking the N2 editing domain and the catalytic core, we speculated that, as a rigid amino acid, the contribution of Pro282 to the enzyme is to keep a proper conformation for the whole enzyme. Therefore, mutation of this key residue might change the protein structure and reduce its stability. We used various methods to assess the effect of the mutation on the protein’s structure/stability. First, we compared the in vivo steady-state protein levels of FLAG-tagged wild-type hmtThrRS and hmtThrRS-P282L after overexpression in HEK293T cells. Western blot analysis using an anti-FLAG antibody showed that the protein level of hmtThrRS-P282L was only 36% of that of the wild-type enzyme (Fig. 4C). Such a reduction might result from a decrease in protein synthesis or faster degradation. However, the point mutation only changes a CCC Pro codon to a CUC Leu codon, both codons being frequently used in humans. Therefore, the decrease in the steady-state level of the P282L protein was more likely to result from faster degradation related to its stability. Consequently, we focused our investigations on the analysis of the protein structure and stability. After purification of hmtThrRS-P282L, we performed a CD analysis of native hmtThrRS and hmtThrRS-P282L. The CD spectrum of wild-type ThrRS was characteristic of an α-helical protein with negative bands at 222 and 208 nm and a positive band at 193 nm (42). However, the spectrum from the P282L mutant was slightly different, with a shift of the 222 and 208 nm peaks toward shorter wavelengths, suggesting structural differences between the two proteins (Fig. 4D). In addition, assuming that such a structural change would affect the binding of a substrate with an extended binding site, such as tRNA*Thr, we measured and compared the dissociation constant (KD) of two proteins for hmttRNA*Thr using a filter binding assay (33, 34). Surprisingly, the KD value of the P282L mutant was decreased compared with that of the native enzyme (0.50 ± 0.04 and 1.83 ± 0.13 μM, respectively) (Fig. 4, E and F), indicating that the mutant binds tRNA*Thr more tightly. Finally, we measured the thermal stability of hmt-
ThrRS and hmtThrRS-P282L after heating at 50 °C. After various incubation times, the residual activity was measured at 37 °C. Whereas the half-life (50% of residual activity) of the native enzyme was greater than 10 min, the half-life of the mutant was only 3.25 min, suggesting that the mutant was more unstable at 50 °C than the wild-type enzyme (Fig. 4G). Taken together, these data indicated strongly that mutation of the conserved Pro282, located between the two domains, alters the structure and stability of hmtThrRS.

We further analyzed whether the structural alteration affected amino acid activation, aminoacylation, and editing capacities. Kinetic parameters in the ATP-PPi exchange reaction showed that the catalytic efficiency ($k_{cat}/K_m$) of Thr activation was only 61% of that of hmtThrRS, caused by an increase in $K_m$ and a decrease in $k_{cat}$ (Table 3). Further aminoacylation kinetic analysis showed that the $k_{cat}$ of the mutant was decreased compared with that of hmtThrRS. The $K_m$ for tRNA was increased 2-fold, and the resulting catalytic efficiency ($k_{cat}/K_m$)
A Point Mutation in hmtThrRS Induces Functional Defects


data showed that both tRNA-independent pretransfer editing and the total editing activity of the mutant were decreased to 15% of wild-type enzyme values (Table 2 and Fig. 5C), whereas the post-transfer editing, as measured in the deacylation assay of Ser-tRNA<sup>Thr</sup>, was negligibly affected (Fig. 5E). Collectively, the data suggested that the replacement of Pro with Leu at position 282 of hmtThrRS alters the structure and/or stability of the enzyme, which in turn has a negative effect on its activities of amino acid activation, tRNA aminoacylation, and proofreading.

**Identification of an Alternative Splice Variant of TARS2—** During the process of cloning of TARS2 from HEK293T cells, a cDNA library was generated by reverse transcription with an oligo(dT) primer. After PCR amplification of the cDNA, two forms of TARS2 were cloned, one being shorter than the expected size (Fig. 6A). DNA sequencing revealed that the shorter isoform lacks 246 nucleotides compared with the wild-type TARS2 mRNA. Deletion of the 246-nt (encoding a peptide ranging from Asn<sup>259</sup> to Arg<sup>340</sup> of hmtThrRS) does not alter the downstream reading frame. By sequence alignment and structure comparison with EcThrRS, we found that the deletion removes part of the N2 editing domain, the aminoacylation domain, and the peptide linker connecting the two domains (data not shown) (17). Analysis of the intron and exon sequences revealed that this isoform could be derived from alternative splicing that skipped exons 8 and 9, ligating exon 10 to 7 directly (Fig. 6B). This in-frame splicing variant was named hmtThrRS-SV to distinguish it from native hmtThrRS.

To explore whether hmtThrRS-SV mRNA is present in other cell types, we designed two primers spanning exon 7 to exon 10 to amplify this region from cDNA libraries of five human cell lines. Both native hmtThrRS and hmtThrRS-SV mRNA were found in these cell lines (Fig. 6C). The relative abundance of the native and splicing variant mRNAs was measured by qPCR in each cDNA sample (Fig. 6D). Two primer sets, one pair specific to the native mRNA spanning exon 8 and exon 9 and the other to the splicing variant mRNAs of the exon 7/10 boundaries, were used. We optimized the qPCR reactions to produce specific DNA fragments with high efficiency. The splicing variant was present in all tested cell lines in proportions ranging between 40 and 26%, with the highest level in BEAS-2B cells (40%) and the lowest level in Jurkat cells (26%) (Fig. 6D).

To determine whether the predicted product of hmtThrRS-SV can fold into a stable protein *in vivo*, we constructed a plasmid harboring hmtThrRS-SV (pCMV-3Tag-3A-hmtThrRS-SV precursor). After transfection into HEK293T cells, it generated a soluble protein with the predicted size (Fig. 6E); however, the amount of hmtThrRS-SV was lower than that of the wild-type hmtThrRS.

**hmtThrRS-SV Is Targeted into Mitochondria but Fails to Form Homodimers—** The mRNA sequence for hmtThrRS-SV has the normal initiation codon at the beginning of the MTS; therefore, we checked whether hmtThrRS-SV could be detected in mitochondria. To this end, the genes of hmtThrRS and hmtThrRS-SV were expressed in HEK293T cells, and their intracellular localizations were observed by confocal microscopy using MitoTracker staining as a mitochondrial marker. As expected, the wild-type hmtThrRS is transported into the mitochondria and co-localizes with the MitoTracker staining (Fig. 7A). Similarly, hmtThrRS-SV co-localizes with the immunofluorescence of MitoTracker, however with a more dispersed,

**TABLE 3**

Kinetic parameters of hmtThrRS and hmtThrRS-P282L for Thr in the activation reaction, as measured in the ATP-PP<sub>e</sub> exchange reaction

| Enzyme     | k<sub>cat</sub> | K<sub>m</sub> | k<sub>cat</sub>/K<sub>m</sub> | Relative |
|------------|----------------|-------------|-----------------------------|----------|
| hmtThrRS   | 5.8 ± 0.2      | 2.5 ± 0.1   | 2.3                         | 100      |
| P282L      | 4.4 ± 0.3      | 3.1 ± 0.3   | 1.4                         | 61       |

**TABLE 4**

Aminoacylation kinetics of hmtThrRS and hmtThrRS-P282L for tRNA<sup>Thr</sup>

| Enzyme     | k<sub>cat</sub> | K<sub>m</sub> | k<sub>cat</sub>/K<sub>m</sub> (X10<sup>-5</sup>) | Relative |
|------------|----------------|-------------|---------------------------------------------|----------|
| hmtThrRS   | 0.061 ± 0.002  | 1.1 ± 0.03  | 55                                          | 100      |
| P282L      | 0.015 ± 0.005  | 2.0 ± 0.2   | 7.5                                         | 13       |
A Point Mutation in hmtThrRS Induces Functional Defects

Drop test shows ScΔthrS strains expressing hmtThrRS, hmtThrRS-P282L, and hmtThrRS-SV with hctRNAThr(AGU). B, complementation phenotypes of ScThrRS and ScThrRS-P310L by Western blotting. GAPDH was used as the internal control. D, quantification of AMP formation in the presence of non-cognate Ser by hmtThrRS with or without tRNA or by hmtThrRS-P282L with or without tRNA. E, deacylation of Ser-[32P]hmttRNAThr by hmtThrRS and hmtThrRS-P282L and the control without the addition of enzyme. Error bars, S.D.

Discussion

Human Mitochondrial ThrRS Misactivates Ser and Mainly Uses tRNA-dependent Editing to Prevent Synthesis of Ser-tRNAThr—For several aaRSs, including class I LeuRS, IleRS, and ValRS and class II ProRS, PheRS, ThrRS, and AlaRS, the editing activity is an essential requisite to ensure accurate tRNA aminoaclylation (4). This seems to be conserved in many bacterial, archaeal, and eukaryotic cytoplasmic synthetases; however, little is known about the editing of aaRS from mitochondria. The restricted metabolic processes occurring in the mitochondria suggest that fewer competing metabolites and amino acids are present in this compartment. However, surprisingly, it appears that mitochondrial aaRS are more specific for their cognate amino acids. This is the case for human mitochondrial LeuRS, which can precisely discriminate Leu from non-cognate Ile thanks to its more accurate amino acid binding pocket. This makes the rejection of Ile at the editing step unnecessary, and indeed, catalytic residues of the editing site have been lost in addition to the editing activity (23). Similarly, yeast mitochondrial PheRS lacks an editing domain but is extremely specific for the generation of Phe-tRNA^{Phe} (24, 25).

Considering the editing of ThrRS, it has been reported that bacterial ThrRS uses post-transfer editing to remove Ser-tRNA^{Thr} (41) and eukaryotic cytoplasmic ThrRS uses tRNA-independent and -dependent pretransfer editing and post-transfer editing to prevent Ser mischarging (20). Most archaeal ThrRS possess an editing domain homologous to D-tyrosyl-tRNA deacetylases (44). However, several cases of archaeal ThrRS lacking an editing domain also have been reported, and a trans-editing factor, containing an anticodon-binding domain, is used to prevent formation of mischarged tRNA^{Thr} (45). On the other hand, SctmThrRS, which naturally lacks the editing domain, only exhibits pretransfer editing to hydrolyze non-cognate Ser adenylate (22). This editing process is incomplete,
and Ser-\text{tRNA}^{\text{Thr}} is produced \textit{in vitro} by ScmtThrRS, which raises the question of the threshold of mischarging endured by the cell (22).

Here, we showed that hmtThrRS does not exhibit an especially specific active site, such as ScmtPheRS or hmtLeuRS, and it significantly misactivates Ser. In return, it exhibits tRNA-independent and tRNA-dependent pretransfer editing, and post-transfer editing activities, to hydrolyze Ser-AMP and Ser-\text{tRNA}^{\text{Thr}}. This may explain why hmtThrRS has an intact editing domain, whereas hmtLeuRS exhibits an inactive one. As reported for ScThrRS (20), we found that post-transfer editing of hmtThrRS was the most efficient way to prevent Ser-\text{tRNA}^{\text{Thr}} synthesis, although it contributed little to the total editing.

\textit{Mutation Causing Human Mitochondrial Encephalomyopathies Affects Protein Structure/Stability and Enzymatic Activities of ThrRS—}Recently, a mutation of Pro to Leu at position 282 of hmtThrRS was identified in a patient presenting mitochondrial disorders (26). Despite decreased levels of protein and charged \text{tRNA}^{\text{Thr}}, the molecular consequence of the mutation could not be understood (26). Here, we compared the activities of the mutant to native hmtThrRS in the amino acid activation, tRNA charging, and editing reactions. All activities were obviously influenced by the mutation. In addition, using a ScThrRS gene deletion strain and analyzing steady-state protein levels, we revealed that this conserved residue also regulates steady-state protein level \textit{in vivo}, which is reasonable, because Pro residues in proteins are often located at key conformational positions. Indeed, Pro^{282} of hmtThrRS is a well conserved site in all eukaryotic ThrRS, and is located in a crucial turn region linking the end of the N2 editing domain and a connecting peptide to the aminoacylation domain. Our data from various analyses suggested that the P282L mutation negatively alters the structure and/or influences protein stability, possibly by affecting the global orientation of the domain or the protein. However, because Pro^{282} is distant from both aminoacylation and editing active sites, and has no potential interac-
a point mutation in hmtThrRS induces functional defects

A, b, and c show mitochondrial import of hmtThrRS-SV and in vivo structural and functional properties. A, both native hmtThrRS and hmtThrRS-SV localize in the mitochondria. HEK293T cells were transfected with the FLAG-tagged constructs of pCMV-3Tag-3A containing the coding sequences for native hmtThrRS or hmtThrRS-SV, respectively. The cells were stained with MitoTracker and immunostained with anti-FLAG. Fluorescent images of MitoTracker (red) and FLAG (green) and the nuclear counterstain DAPI (blue) were captured by a confocal microscope. Scale, 20 μm. B, HEK293T cells were co-transfected with pCMV-3Tag-4A-hmtThrRS (c-Myc-tagged hmtThrRS) in the presence of pCMV-3Tag-3A-hmtThrRS (FLAG-tagged hmtThrRS) or control vector pCMV-3Tag-3A. The same procedures were performed for hmtThrRS-SV. Cell lysates were immunoprecipitated with anti-FLAG antibodies conjugated to agarose beads. Western blotting was used to detect whether c-Myc-tagged proteins were co-immunoprecipitated with FLAG-tagged proteins. C, a shuffle assay showing that the ScThrRS-SV could not complement the ScΔthrS strain. Wild-type ScThrRS and empty vector p425TEF were used as controls.

Existence of an Alternative Splicing Variant with Possible Non-translational Function—Recently, it was reported that nearly all aaRS genes in humans encode multiple splicing variants, creating a large number of aaRS-related catalytic nulls (28). These catalytic nulls usually keep their non-catalytic domains and exhibit deletions or truncations in the catalytic core, inducing loss of tRNA aminoacylation activity. Although some of these proteins have been detected in cell extracts by Western blotting, their physiological functions remain to be determined. Here, we identified a TARS2 splicing variant in several human cell lines, which encodes a hmtThrRS derivative lacking a peptide covering a portion of both the editing and the aminoacylation domains. Our data revealed that this mutant is unable to dimerize and cannot complement a yeast strain deleted for the ThrRS gene, suggesting that it is deficient in catalyzing Thr-tRNA Thr formation for protein synthesis. Meanwhile, we found that the protein could not be purified and it formed inclusion bodies in E. coli (data not shown), because skipping exon 8 and 9 causes a drastic protein deletion, which affects the N2 editing domain, catalytic core, and dimer interface with putative effects on protein dimerization (data not shown) (17). The data also showed that the splicing variant is readily translated and imported into mitochondria. It has been shown that mitochondria may contain aaRS-like proteins that play crucial roles in mitochondria metabolism. For example, a seryl-tRNA synthetase-like protein is found in mitochondria from insects, the deletion of which causes alterations in mitochondrial structure, function, and biogenesis without connection to tRNA Ser aminoacylation (46). Similarly, the catalytically inactive splicing variant of ThrRS identified here may have some non-canonical function besides tRNA Thr aminoacylation, and this needs to be explored functionally.

Author Contributions—Y. W., X. L. Z., and Z. R. R. performed the experiments. R. J. L. analyzed protein structure. G. E. analyzed the data. X. L. Z. and E. D. W. designed the experiments, analyzed the data, and wrote the paper.
A Point Mutation in hmtThrRS Induces Functional Defects

polypeptides. J. Am. Chem. Soc. 87, 218–228
43. Liu, Y., Satz, J. S., Vo, M. N., Nangle, L. A., Schimmel, P., and Ackerman, S. L. (2014) Deficiencies in tRNA synthetase editing activity cause cardioproteinopathy. Proc. Natl. Acad. Sci. U.S.A. 111, 17570–17575
44. Hussain, T., Kruparani, S. P., Pal, B., Dock-Bregeon, A. C., Dwivedi, S., Shekar, M. R., Sureshbabu, K., and Sankaranarayanan, R. (2006) Post-transfer editing mechanism of a D-aminoacyl-tRNA deacylase-like domain in threonyl-tRNA synthetase from archaea. EMBO J. 25, 4152–4162
45. Korencic, D., Ahel, I., Schelert, J., Sacher, M., Ruan, B., Stathopoulos, C., Blum, P., Ibba, M., and Söll, D. (2004) A freestanding proofreading domain is required for protein synthesis quality control in Archaea. Proc. Natl. Acad. Sci. U.S.A. 101, 10260–10265
46. Guitart, T., Leon Bernardo, T., Sagalés, J., Stratmann, T., Bernués, J., and Ribas de Pouplana, L. (2010) New aminoacyl-tRNA synthetase-like protein in insects with an essential mitochondrial function. J. Biol. Chem. 285, 38157–38166
47. Claros, M. G., and Vincens, P. (1996) Computational method to predict mitochondrially imported proteins and their targeting sequences. Eur. J. Biochem. 241, 779–786
